News Merck sets sights on Epstein-Barr virus jab with Opko deal Licensing agreement includes $50m upfront, with a total value of $922.5m, including milestones.
News Growth hormone could be filed without further trials, says O... Drug could be filed after "outlier" analysis.
News OPKO weekly growth hormone jab fails in phase 3 US biotech OPKO Health has said it will continue with clinical development of its long-acting human growth hormone product (hGH-CTP), even though it has failed in a late stage trial in adul
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
